Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis.
A heterogeneity of CCK2 receptors has been reported which could correspond to different states of coupling to G proteins and/or association with different second messenger systems. To investigate these hypotheses, the wild-type CCK2 receptor and three mutants F347A, D100N and K333M/K334T/R335L, expected to modify the coupling of the G protein with the third intracellular loop of the receptor, were transfected into Cos-7 cells and their binding and signalling properties were evaluated using the natural ligand CCK8. Activation of wild-type as well as F347A, D100N or K333M/K334T/R335L CCK2 receptors by this ligand led to a similar arachidonic acid release which was blocked by pertussis toxin and the phospholipase A2 inhibitor, mepacrine. Nevertheless, in contrast to the wild-type CCK2 receptor, addition of CCK8 to cells transfected with the F347A or K333M/K334T/R335L mutants did not result in the production of inositol phosphates while the maximum increase in this second messenger formation was reduced by 30% with the D100N mutant. Taken together, these results suggest that the CCK2 receptor is coupled to two G proteins and that Phe347 and the cluster of basic residues K333/K334/R335 probably play a key role in Gq protein stimulation leading to inositol phosphate production but not in activation of the G protein coupled to phospholipase A2. These data bring additional support at the molecular level to the existence of different affinity states of CCK2 receptors suggested from the results of binding assays and behavioural studies.
Pommier
Blandine
B
Département de Pharmacochimie Moléculaire et Structurale, Université René Descartes, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
Marie-Claire
Cynthia
C
Da Nascimento
Sophie
S
Wang
Hung-Li
HL
Roques
Bernard P
BP
Noble
Florence
F
D019943:Amino Acid Substitution; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001667:Binding, Competitive; D019556:COS Cells; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007295:Inositol Phosphates / Q000096:biosynthesis; D008024:Ligands; D016297:Mutagenesis, Site-Directed; D037342:Pertussis Toxin / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D011869:Radioligand Assay; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D012844:Sincalide / Q000493:pharmacokinetics; D014162:Transfection; D014316:Tritium
D004791:Enzyme Inhibitors; D007295:Inositol Phosphates; D008024:Ligands; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D014316:Tritium; D016718:Arachidonic Acid; D037342:Pertussis Toxin; D010741:Phospholipases A; D054467:Phospholipases A2; D012844:Sincalide